Gemini Therapeutics

Gemini was formed to redefine AMD and linked disorders with precision medicine. Gemini merged with Disc Medicine in December 2022.

There’s a strong foundation of human genetics research in AMD - more than a decade of data which is largely untapped by biopharma. We think the time is right to harness these genetic insights, and we’ve gathered the people, the technology and the resources necessary to lead the translational effort. Our precision approach allows us to accelerate the development of novel therapeutics for AMD patients with a high genetic risk profile. James McLaughlin, co-founder, Gemini Therapeutics